Cure SMA Awards $150,000 Grant to Chad Heatwole, MD, University of Rochester

Cure SMA has awarded a $150,000 research grant to Chad Heatwole, MD, at the University of Rochester, for his project, ” Development of a Clinically Relevant Outcome Measure for Pediatric SMA Therapeutic Trials.” Dr. Heatwole and his team are working to develop SMA-specific patient reported outcome measures for use in SMA clinical trials and clinics. […]

Cure SMA Awards $150,000 Grant to Chad Heatwole, MD, University of Rochester Read More »

Uniting the SMA Community Through Local Programs and Support

After her son William’s SMA type 2 diagnosis in April 2001, Heidi Johnson’s doctor immediately showed her the Cure SMA (then Families of SMA) website and said to look for support within the SMA community. “After arriving home, we took the doc’s advice and opened up [the website] where we felt the most amazing support.

Uniting the SMA Community Through Local Programs and Support Read More »

Invitae Partners with Biogen to Offer Free Genetic Testing for SMA

Invitae Corporation recently announced that it will partner with Biogen to offer genetic testing at no charge to patients who may have spinal muscular atrophy (SMA). The program is called SMA Identified, and is intended to more quickly diagnose patients who may have SMA, or confirm a clinical diagnosis of SMA. The test also reports

Invitae Partners with Biogen to Offer Free Genetic Testing for SMA Read More »

Dr. Richard Finkel, M.D., Honored with the American Academy of Neurology’s 2018 Sidney Carter Award in Child Neurology

Richard Finkel, M.D., the chief of neurology at Nemours Children’s Hospital in Orlando, Fla., was honored with the American Academy of Neurology’s 2018 Sidney Carter Award in Child Neurology, in recognition of his achievements in treating children with muscular dystrophy (MD) and spinal muscular atrophy (SMA). Dr. Finkel’s presentation in receipt of the Sidney Carter

Dr. Richard Finkel, M.D., Honored with the American Academy of Neurology’s 2018 Sidney Carter Award in Child Neurology Read More »

AveXis to Present Phase 1 Data at the 70th American Academy of Neurology Annual Meeting

The Phase 1, open-label, dose-escalation trial was designed to evaluate the safety and tolerability of AVXS-101 in patients with SMA Type 1. The key measures of efficacy were the time from birth to an event and video confirmed achievement of ability to sit unassisted. Additionally, several exploratory objective measures were assessed, including a standard motor

AveXis to Present Phase 1 Data at the 70th American Academy of Neurology Annual Meeting Read More »

SMA Community Leaders to Gather in Washington DC to Network, Learn and Advocate

On Thursday, April 26, more than 70 chapter leaders, event organizers and board/committee members, representing 24 states and DC, will gather in Washington DC for two days of networking, learning, and advocacy. The activities include a day of advocacy on Capitol Hill, meeting with House and Senate offices, and a day of training and information

SMA Community Leaders to Gather in Washington DC to Network, Learn and Advocate Read More »

There is Still Time to Complete Cure SMA’s 2018 Community Survey

Dear Members of the SMA Community, For the past several years, we’ve been working to collect data and information on our community’s experiences, goals, hopes, and challenges. We know that the voice of our community is powerful. By sharing our stories, we can communicate our priorities to the FDA and regulators, provide insight into daily

There is Still Time to Complete Cure SMA’s 2018 Community Survey Read More »

Biogen Presents New Data at the American Academy of Neurology (AAN) Annual Meeting

Biogen recently presented new data on Spinraza for the treatment of spinal muscular atrophy (SMA) during the 70th American Academy of Neurology (AAN) Annual Meeting, currently taking place from April 21-27 in Los Angeles, California. Both platform and poster presentations highlighted the benefits Spinraza provides for individuals with spinal muscular atrophy (SMA) across the age

Biogen Presents New Data at the American Academy of Neurology (AAN) Annual Meeting Read More »

Spring 2018 Issue of Compass Now Available Online

The Spring 2018 issue of Compass is now available online. The issue covers Cure SMA’s newborn screening efforts, including how NBS can help children diagnosed with SMA, the addition of SMA to the federal Recommended Uniform Screening Panel (RUSP), and state and federal advocacy efforts. For a condition like SMA to become part of routine

Spring 2018 Issue of Compass Now Available Online Read More »

Scroll to Top